-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
What Kind Of Shareholders Hold The Majority In Getein Biotech, Inc's (SHSE:603387) Shares?
What Kind Of Shareholders Hold The Majority In Getein Biotech, Inc's (SHSE:603387) Shares?
The big shareholder groups in Getein Biotech, Inc (SHSE:603387) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
Getein Biotech has a market capitalization of CN¥6.6b, so we would expect some institutional investors to have noticed the stock. In the chart below, we can see that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Getein Biotech.
View our latest analysis for Getein Biotech
SHSE:603387 Ownership Breakdown August 3rd 2022What Does The Institutional Ownership Tell Us About Getein Biotech?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in Getein Biotech. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Getein Biotech, (below). Of course, keep in mind that there are other factors to consider, too.
SHSE:603387 Earnings and Revenue Growth August 3rd 2022Hedge funds don't have many shares in Getein Biotech. Looking at our data, we can see that the largest shareholder is En Ben Su with 40% of shares outstanding. For context, the second largest shareholder holds about 4.4% of the shares outstanding, followed by an ownership of 1.6% by the third-largest shareholder.
We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
Insider Ownership Of Getein Biotech
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our information suggests that insiders maintain a significant holding in Getein Biotech, Inc. It has a market capitalization of just CN¥6.6b, and insiders have CN¥2.8b worth of shares in their own names. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 46% stake in Getein Biotech. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
It seems that Private Companies own 4.4%, of the Getein Biotech stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Getein Biotech (at least 1 which can't be ignored) , and understanding them should be part of your investment process.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Getein Biotech,Inc.(上海證券交易所代碼:603387)的大股東集團擁有對公司的控制權。大公司通常有機構作為股東,我們通常會看到內部人士持有小公司的股份。沃倫·巴菲特説,他喜歡“一家由有能力、以所有者為導向的人經營的、具有持久競爭優勢的企業”。因此,看到一些內部人持股是件好事,因為這可能表明管理層是以所有者為導向的。
Getein Biotech的市值為66億元人民幣,因此我們預計一些機構投資者已經注意到了這隻股票。在下面的圖表中,我們可以看到機構投資者買入了該公司的股票。讓我們仔細看看不同類型的股東能告訴我們關於Getein Biotech的什麼。
查看我們對Getein Biotech的最新分析
上海證交所:603387所有權明細2022年8月3日關於Getein Biotech,機構所有權告訴了我們什麼?
機構投資者通常將自己的回報與經常跟蹤的指數的回報進行比較。因此,他們通常確實會考慮收購被納入相關基準指數的較大公司。
正如你所看到的,機構投資者在Getein Biotech擁有相當多的股份。這表明在專業投資者中有一定的可信度。但我們不能僅僅依靠這一事實,因為機構有時會做出糟糕的投資,就像每個人一樣。如果兩個大型機構投資者試圖同時拋售一隻股票,股價大幅下跌的情況並不少見。因此,看看Getein Biotech過去的盈利軌跡是值得的(見下圖)。當然,請記住,還有其他因素需要考慮。
上海證交所:603387收益和收入增長2022年8月3日對衝基金在Getein Biotech的股份並不多。看看我們的數據,我們可以看到,最大的股東是恩本蘇,持有40%的流通股。作為參考,第二大股東持有約4.4%的流通股,第三大股東持有1.6%的股份。
我們還觀察到,前7名股東佔股東名冊的一半以上,少數小股東在一定程度上平衡了大股東的利益。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。目前,我們沒有注意到分析師對該股的報道,因此該公司不太可能被廣泛持有。
Getein Biotech的內部所有權
儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們的信息顯示,內部人士持有Getein Biotech,Inc.的大量股份。該公司的市值僅為66億元人民幣,內部人士以自己的名義持有價值28億元的股票。這可能表明,創始人仍持有大量股份。您可以單擊此處查看他們是在買入還是在賣出。
一般公有制
公眾通常是個人投資者,他們持有Getein Biotech 46%的股份。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私營公司所有權
看起來,私營公司擁有Getein Biotech 4.4%的股份。僅從這一事實很難得出任何結論,因此值得調查一下誰擁有這些私營公司。有時,內部人士或其他關聯方通過一家獨立的私人公司擁有上市公司的股份。
接下來的步驟:
雖然考慮擁有一家公司的不同集團是很值得的,但還有其他更重要的因素。例如,考慮一下無處不在的投資風險幽靈。我們已經確定了兩個警告信號與Getein Biotech(至少1個不容忽視)合作,瞭解它們應該是你投資過程的一部分。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費令人感興趣的公司名單,有強勁的財務數據支持。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧